Kluwer Patent Blog

Novartis v. Actavis, Oslo District Court (Oslo tingrett), 10 February 2011

Kaja Veel Midtbø · Thursday, May 26th, 2011 · Landmark European Patent Cases

The Court, in infringement proceedings brought by Novartis against Actavis for marketing generic Valsartan, held that the assessment of infringement had to be made as of the time of infringement, not as of the priority date. This is the first decision in years in Norway taking a position on this issue.

The judgement also deals with the scope of Novartis SPC for Valsartan, which the Court held to protect both mono products and combination products with Valsartan and HCTZ.

Click here for the full text of this case.

A full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer

Leading change



This entry was posted on Thursday, May 26th, 2011 at 3:42 pm and is filed under (Indirect) infringement, Case Law, Norway, SPC

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.